MILLIPLEX^® Human Neuroscience Panel

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 4 analytes in human cerebrospinal fluid (CSF).Analytes included: Amyloid beta 1-40 (Aβ40), Amyloid beta 1-42 (Aβ42), Total Tau proteins (tTau), and Phosphorylated Tau Thr181 (pTau181).Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Harness Mutliplexing Efficiency: Simultaneously measure both Aβ40 and Aβ42 in a single assay, accelerating your neurodegenerative disease research while maximizing laboratory throughput.Built-in Reliability: Every kit undergoes rigorous validation to deliver unwavering consistency across batches, giving you the confidence to pursue breakthrough discoveries without questioning your data integrity.Biologically Relevant Results: Our specially formulated serum matrix replicates physiological conditions, ensuring your findings accurately measure the analytes of interest.Complete Research Solution: Eliminate procurement headaches with our comprehensive kit containing all essential components, allowing you to focus on scientific discovery rather than logistical challenges.Accelerate Scientific Impact: Transform precise biomarker measurements into actionable insights that drive forward our understanding of Alzheimer′s disease and related amyloidopathies.

Alzheimer′s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia, affecting approximately 36 million people worldwide. The disease is characterized by two key features: extracellular amyloid β (Aβ) plaques formed from peptides like Aβ1-40 and Aβ1-42, and intracellular neurofibrillary tangles composed of hyperphosphorylated Tau protein. These biomarkers—reduced soluble Aβ1-42, increased total Tau, and phosphorylated Tau in cerebrospinal fluid—serve as critical indicators of the pathological processes underlying neurodegenerative conditions.